13F HOLDINGS REPORT
Flagship Pioneering Inc.
Quarter ended Q2 2023 · Filed May 15, 2023 · Accession 0000950123-23-005258
Total Value
$2.57B
Positions
22
Other Managers
3
Confidential Omitted
No
Holdings (22)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Moderna Inc | MRNA | 12,882,819 | $1.98B | 76.88% |
| 2 | Omega Therapeutics Inc | 68217N105 | 22,240,723 | $134.1M | 5.21% |
| 3 | Seres Therapeutics Inc | MCRB | 14,664,169 | $83.1M | 3.23% |
| 4 | Sana Biotechnology Inc | SANA | 21,166,448 | $69.2M | 2.69% |
| 5 | Denali Therapeutics Inc | DNLI | 2,619,968 | $60.4M | 2.35% |
| 6 | Foghorn Therapeutics Inc | FHTX | 9,330,878 | $57.9M | 2.25% |
| 7 | Seres Therapeutics Inc | MCRB | 8,452,876 | $47.9M | 1.86% |
| 8 | Sana Biotechnology Inc | SANA | 13,072,570 | $42.7M | 1.66% |
| 9 | Omega Therapeutics Inc | 68217N105 | 6,984,856 | $42.1M | 1.64% |
| 10 | Foghorn Therapeutics Inc | FHTX | 3,343,242 | $20.7M | 0.81% |
| 11 | Axcella Health Inc | 05454B105 | 18,142,125 | $8.7M | 0.34% |
| 12 | Sigilon Therapeutics Inc | 82657L107 | 8,888,888 | $8.3M | 0.32% |
| 13 | Evelo Biosciences Inc | EVEX-WT | 30,059,382 | $5.4M | 0.21% |
| 14 | Axcella Health Inc | 05454B105 | 11,109,420 | $5.3M | 0.21% |
| 15 | Syros Pharmaceuticals Inc | 87184Q206 | 700,000 | $1.9M | 0.07% |
| 16 | Evelo Biosciences Inc | EVEX-WT | 10,205,282 | $1.8M | 0.07% |
| 17 | Evelo Biosciences Inc | EVEX-WT | 10,162,664 | $1.8M | 0.07% |
| 18 | Sigilon Therapeutics Inc | 82657L107 | 1,481,481 | $1.4M | 0.05% |
| 19 | Syros Pharmaceuticals Inc | 87184Q206 | 293,848 | $784,574 | 0.03% |
| 20 | Moderna Inc | MRNA | 3,924 | $602,648 | 0.02% |
| 21 | Codiak Biosciences Inc | 192010106 | 3,054,687 | $533,043 | 0.02% |
| 22 | Codiak Biosciences Inc | 192010106 | 485,949 | $84,798 | 0.00% |